Literature DB >> 3065084

High molecular weight epithelial mucins as markers in breast cancer.

M R Price1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3065084     DOI： 10.1016/0277-5379(88)90088-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  8 in total

1.  Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

Authors:  P X Xing; K Reynolds; G A Pietersz; I F McKenzie
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 2.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

3.  Significance of Proline Residue on Short Mucin Peptide Interactions with Mouse MUC1 Monoclonal Antibody Studied by Saturation Transfer Difference NMR Spectroscopy.

Authors:  Cheng Her; William M Westler; Thao Yang
Journal:  JSM Chem       Date:  2013-10-17

4.  Reactivity of an anti-(human gastric carcinoma) monoclonal antibody with core-related peptides of gastrointestinal mucin.

Authors:  M R Price; M Sekowski; G Y Yang; L G Durrant; R A Robins; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Immune Responses to the MUC1 Mucin.

Authors:  Graeme Denton; Michael R Price
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

6.  Elements of secondary structure in a human epithelial mucin core peptide fragment.

Authors:  S J Tendler
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

7.  C595--a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas.

Authors:  M R Price; J A Pugh; F Hudecz; W Griffiths; E Jacobs; I M Symonds; A J Clarke; W C Chan; R W Baldwin
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

8.  Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.

Authors:  S Adluri; T Gilewski; S Zhang; V Ramnath; G Ragupathi; P Livingston
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.